Patient experience of participation within the CAIN trial, a phase 1 clinical trial evaluating the effectiveness and safety profile of the HistoSonics Histotripsy System in treating primary solid renal tumours.
Loading...
All Authors
Brandon, J.
Zhong, J.
Wah, T M
LTHT Author
Brandon, Jacqueline
Zhong, Jim
Wah, Tze Min
Zhong, Jim
Wah, Tze Min
LTHT Department
Research & Innovation
Abdominal Medicine & Surgery
Hepatobiliary Surgery
Radiology
Abdominal Medicine & Surgery
Hepatobiliary Surgery
Radiology
Non Medic
Publication Date
2025
Item Type
Conference Abstract
Language
Subject
Subject Headings
Abstract
Purpose:
The CAIN trial successfully delivered the global-first translation of histotripsy technology in renal cancer treatment (Leeds Teaching Hospitals NHS Trust, 2023). The aim of this patient-focused study was to gather insights into the participants’ experience.
Material and Methods:
The UK National Institute of Health Research (NIHR) Participant in Research Experience Survey (PRES) was provided to all participants treated between 01/03/2023-01/11/2024. Completion of the survey was voluntary, and responses anonymised. Data were extracted to measure demographics, Likert scale responses of research experience and free-text comments.
Results:
All study participants (n=8) responded.
Demographics: All white British ethnicity, female/male (2/6), Age groups [60-69 (n=2), 70-79 (n=3), 80-89 (n=1), non-stated (n=2)].
All participants stated this was the first research trial they had participated in.
All agreed (n=2) or strongly agreed (n=6) they would take part in research again.
All agreed (n=1) or strongly agreed (n=7) they felt well prepared for the trial by the information provided in advance.
All agreed (n=2) or strongly agreed (n=6) they felt their participation had been valued.
All agreed (n=2) or strongly agreed (n=6) they had been treated with courtesy and respect.
Participants' free-text comments identified key themes of altruism, and the desire to contribute to medical science and the development of future treatments and technologies.
Conclusion:
Participants were prepared to try novel therapy despite absence of long-term data, with high levels of motivation to help others and future technologies. High levels of satisfaction were reported for participating in this early-phase innovative, novel trial treatment, with willingness to participate in future trials.